Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines. Its product candidates include SG295 and SG242 that target CD19+ cancer cells,including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus. SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease.
